IBT specializes in delivering top-notch reagents tailored for research and development purposes.
An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
At IBT Bioservices, we understand the critical need for effective interventions against Streptococcus pneumonia infections. We specialize in comprehensive preclinical testing services aimed at assessing the safety and efficacy of potential treatments and vaccines against this versatile and virulent species of bacterium.
Pneumonia, Bacteremia, and meningitis
Elderly, young children, and immunocompromised humans
Fever, cough, chills, shortness of breath, chest pain, and in some cases, mental confusion, disorientation.
Streptococcus pneumonia is a gram-positive facultative anaerobic bacterium. The diseases caused by Strep pneumonia contribute to a public health problem worldwide, affecting both developed and underdeveloped countries. It is crucial to continue researching and developing protective and therapeutic interventions.
Streptococcus pneumonia is a significant pathogen responsible for causing severe infections, including bloodstream infections, pneumonia, and meningitis. This bacterium has several virulence factors, such as pneumolysin, adhesins, biofilm formation and antibiotic resistance, that can make it challenging to treat, making it crucial to develop novel therapies to combat these infections.
At IBT, our expert team of scientists has deep expertise in the biology of S. pneumonia. It utilizes state-of-the-art facilities and advanced methodologies to perform thorough preclinical in vitro and in vivo testing for Streptococcus pneumonia.
Target Virulence Factors
Understand Pathogenesis
Reduce Disease Burden
Understanding how potential interventions are absorbed, distributed, metabolized, and eliminated by the body is crucial. Our comprehensive pharmacokinetic studies provide valuable insights into the intervention’s behavior, bioavailability, and optimal dosage. Additionally, toxicology evaluations ensure the safety of the treatment or vaccine candidates, assessing potential adverse effects and determining the appropriate dosage range.
Using advanced molecular and cellular techniques, we evaluate the efficacy of potential drugs and vaccines against Streptococcus pneumonia. These studies help identify compounds that can effectively inhibit bacterial growth, disrupt virulence factors, enhance host immune response or review mechanism of actions. We help clients assess their therapeutic candidates and investigate the mechanisms of action of potential interventions, providing valuable insights into their ability to combat Streptococcus pneumonia infections. IBT can offer a variety of assays to support your research, for example, ELISA, Luminex, flow cytometry and toxin-based viability assays.
At IBT, we are dedicated to advancing the field of Streptococcus pneumonia research and development through reliable and accurate in vitro and in vivo preclinical testing services. Our commitment to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this bacterial infection. We provide you with high quality data and documentation supporting your regulatory filings.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat.